Pseudo-ginsenoside GQ

Drug Profile

Pseudo-ginsenoside GQ

Alternative Names: PGQ

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jilin Huakang Pharmaceutical
  • Developer Jilin Huakang Pharmaceutical; Jilin University
  • Class Cardiovascular therapies; Ginsenosides; Ischaemic heart disorder therapies; Saponins
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Angina pectoris
  • No development reported Myocardial ischaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Myocardial-ischaemia in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top